7- cyano- 2,3,4,5- tetrahydro- 1- (1H- imidazol- 4- ylmethyl)- 3- (phenylmethyl)- 4- (2- thienylsulfonyl)- 1H- 1,4- benzodiazepine (BMS 214662)

a farnesyltransferase inhibitor; structure in first source

Also Known As:

BMS 214662; BMS-214662

Networked: 21 relevant articles (1 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: 21
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - Benzodiazepines: 8452
        7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: 21

Experts

1.	Wright, John: 3 articles (07/2006 - 04/2005)
2.	Copland, Mhairi: 2 articles (11/2009 - 03/2008)
3.	Holyoake, Tessa L: 2 articles (11/2009 - 03/2008)
4.	Pellicano, Francesca: 2 articles (11/2009 - 03/2008)
5.	Martell, Robert E: 2 articles (06/2007 - 03/2005)
6.	Clark, Jeffrey W: 2 articles (07/2006 - 04/2004)
7.	Cooper, Michael: 2 articles (07/2006 - 04/2005)
8.	Eder, Joseph P: 2 articles (07/2006 - 04/2004)
9.	Ryan, David P: 2 articles (07/2006 - 04/2004)
10.	Supko, Jeffrey G: 2 articles (07/2006 - 04/2004)

Related Diseases

1.	Blast Crisis (Blast Phase) 03/01/2008 - "BMS-214662 was cytotoxic against CML blast crisis stem/progenitor cells, particularly in combination with a tyrosine kinase inhibitor and equally effective in cell lines harboring wild-type vs mutant BCR-ABL, including the T315I mutation. " 07/01/2011 - "PD184352 increased the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. "
2.	Neoplasms (Cancer) 04/01/2004 - "The main objective of the study was to determine the dose-limiting toxicities and the maximum tolerated dose of BMS-214662 when administered as a single dose i.v. over 1 h every 21 days to patients with advanced solid tumors. " 10/15/2001 - "In a study performed using Calu-1 tumor-bearing mice, no obvious schedule dependency of BMS-214662 was observed. " 04/10/2005 - "BMS-214662 induced apoptosis in tumors but did not inhibit MAPK signaling. " 04/10/2005 - "The objectives were to determine the dose-limiting toxicities and the recommended dose (RD), to describe PKs, and to evaluate the relationships between BMS-214662 exposure, FT inhibition, downstream signaling, and induction of apoptosis in tumor samples. " 06/01/2004 - "BMS-214662 is the most potent apoptotic FTI known and exhibits curative responses in mice bearing a variety of staged human tumor xenografts such as HCT-116 human colon tumor. "
3.	Leukemia 10/01/2002 - "Administration of BMS-214662 as a weekly intravenous infusion produced a decrease in bone marrow blasts of greater than 50% in 23% of patients with acute leukemia or MDS; 18% achieved normalization of blast counts to less than 5%. " 04/20/2005 - "Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes." 04/20/2005 - "To investigate the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of BMS-214662, a farnesyl transferase (FTase) inhibitor, in patients with acute leukemias and high-risk myelodysplastic syndromes (MDS). "
4.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 04/20/2005 - "Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes." 04/20/2005 - "To investigate the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of BMS-214662, a farnesyl transferase (FTase) inhibitor, in patients with acute leukemias and high-risk myelodysplastic syndromes (MDS). "
5.	Myeloid Leukemia (Leukemia, Myelocytic) 08/01/2003 - "Several FTIs (eg BMS-214662, L-778,123, R-115777 and SCH66336) have entered phase I and phase II clinical trials in myeloid leukemias. "

Related Drugs and Biologics

1.	Tyrosine Kinase Inhibitors
2.	Transferases
3.	Farnesyltranstransferase (Farnesyltransferase)
4.	tipifarnib (R115777)
5.	Paclitaxel (Taxol)
6.	L 778,123
7.	lonafarnib (SCH 66336)
8.	Carboplatin (JM8)
9.	Proteins (Proteins, Gene)
10.	Cisplatin (Platino)

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Infusions